These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21623930)

  • 1. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity.
    Arellano I; Cestari T; Ocampo-Candiani J; Azulay-Abulafia L; Bezerra Trindade Neto P; Hexsel D; Machado-Pinto J; Muñoz H; Rivitti-Machado MC; Sittart JA; Trindade de Almeida AR; Rego V; Paliargues F; Marques-Hassun K
    J Eur Acad Dermatol Venereol; 2012 May; 26(5):611-8. PubMed ID: 21623930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma.
    Grimes PE; Bhawan J; Guevara IL; Colón LE; Johnson LA; Gottschalk RW; Pandya AG
    J Am Acad Dermatol; 2010 Jun; 62(6):962-7. PubMed ID: 20398959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma.
    Monheit GD; Dreher F
    J Drugs Dermatol; 2013 Mar; 12(3):270-4. PubMed ID: 23545908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy.
    Cestari TF; Hexsel D; Viegas ML; Azulay L; Hassun K; Almeida AR; Rêgo VR; Mendes AM; Filho JW; Junqueira H
    Br J Dermatol; 2006 Dec; 156 Suppl 1():13-20. PubMed ID: 17176300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads.
    Torok H; Taylor S; Baumann L; Jones T; Wieder J; Lowe N; Jarret M; Rich P; Pariser D; Tschen E; Martin D; Menter A; Weiss J
    J Drugs Dermatol; 2005; 4(5):592-7. PubMed ID: 16167418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
    Chan R; Park KC; Lee MH; Lee ES; Chang SE; Leow YH; Tay YK; Legarda-Montinola F; Tsai RY; Tsai TH; Shek S; Kerrouche N; Thomas G; Verallo-Rowell V
    Br J Dermatol; 2008 Sep; 159(3):697-703. PubMed ID: 18616780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study.
    Rendon M; Cardona LM; Bussear EW; Benitez AL; Colón LE; Johnson LA
    Cutis; 2008 Nov; 82(5):372-8. PubMed ID: 19090343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Tranexemic Acid With Triple Combination Cream (Flucinolone+Hydroquinone+Tretinoin) Versus Triple Combination Cream Alone In Treatment Of Melasma.
    Basit A; Rahman A; Uddin R
    J Ayub Med Coll Abbottabad; 2021; 33(2):293-298. PubMed ID: 34137548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.
    Taylor SC; Torok H; Jones T; Lowe N; Rich P; Tschen E; Menter A; Baumann L; Wieder JJ; Jarratt MM; Pariser D; Martin D; Weiss J; Shavin J; Ramirez N
    Cutis; 2003 Jul; 72(1):67-72. PubMed ID: 12889718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma.
    Ferreira Cestari T; Hassun K; Sittart A; de Lourdes Viegas M
    J Cosmet Dermatol; 2007 Mar; 6(1):36-9. PubMed ID: 17348994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma.
    Grimes PE
    Cutis; 2007 Dec; 80(6):497-502. PubMed ID: 18246882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community-based trial of a triple-combination agent for the treatment of facial melasma.
    Grimes P; Kelly AP; Torok H; Willis I
    Cutis; 2006 Mar; 77(3):177-84. PubMed ID: 16610738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved quality of life with effective treatment of facial melasma: the pigment trial.
    Balkrishnan R; Kelly AP; McMichael A; Torok H
    J Drugs Dermatol; 2004; 3(4):377-81. PubMed ID: 15303781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma.
    Figueiredo Souza L; Trancoso Souza S
    Dermatol Ther; 2012; 25(5):477-80. PubMed ID: 23046029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melasma in Latin America: options for therapy and treatment algorithm.
    Cestari T; Arellano I; Hexsel D; Ortonne JP;
    J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):760-72. PubMed ID: 19646135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma.
    Goldman MP; Gold MH; Palm MD; Colón LE; Preston N; Johnson LA; Gottschalk RW
    Dermatol Surg; 2011 Feb; 37(2):224-33. PubMed ID: 21269349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective assessment of erythema and pigmentation of melasma lesions and surrounding areas in long-term management regimens with triple combination.
    Hexsel D; Soirefmann M; Fernandes JD; Siega C
    J Drugs Dermatol; 2014 Apr; 13(4):444-8. PubMed ID: 24719064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating epidermal melasma with a 4% hydroquinone skin care system plus tretinoin cream 0.025%.
    Grimes P; Watson J
    Cutis; 2013 Jan; 91(1):47-54. PubMed ID: 23461059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma.
    Torok HM; Jones T; Rich P; Smith S; Tschen E
    Cutis; 2005 Jan; 75(1):57-62. PubMed ID: 15732437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream.
    Bhawan J; Grimes P; Pandya AG; Keady M; Byers HR; Guevara IL; Colón LE; Johnson LA; Gottschalk R
    Am J Dermatopathol; 2009 Dec; 31(8):794-8. PubMed ID: 19755910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.